CI direc

CMP: ₹ 3722

Target: ₹ 4040 (9%) Target Period: 12 months

May 9, 2022

Focus continues on order wins, embarked capex...

About the stock: Navin Fluorine (NFIL) operates one of the largest integrated fluorochemicals complexes in India with a presence in speciality chemicals, CRAMS, inorganic fluoride and refrigerant segments.

- The company has two manufacturing facilities in Surat and Dewas while it is setting up a new greenfield capacity at Dahej
- In terms of revenue contribution, speciality chemical constitutes 40% of overall revenue followed by CRAMS of 25% and the rest from refrigerant (~18%) and inorganic fluoride (~17%) businesses

Q4FY22 Results: The topline was largely in line while margins missed due to lower than anticipated gross margins.

- Reported revenue growth was 21.6% YoY to ₹ 409 crore, led by speciality chemical (up 21.4% YoY), inorganic fluoride (up 20.3% YoY), refrigerants (up 37.9% YoY). Revenue from CRAMS was up 15.8% YoY to ₹ 88 crore
- Gross margins were down 36 bps YoY to 51.9% while EBITDA margin contracted 200 bps YoY to 23%, due to higher other cost (up 29% YoY)
- EBITDA was up 12% YoY to ₹ 94.3 crore
- Adjusted PAT increased 19% YoY to ₹ 70.9 crore

What should investors do? The stock appreciated at 72% CAGR in last three years.

We retain HOLD rating on the back of better growth outlook from value added segments such as CRAMS and speciality chemical

Target Price and Valuation: We value Navin Fluorine at 45x P/E FY24E EPS to arrive at a target price of ₹ 4040/share (earlier ₹ 4520/share).

Key triggers for future price performance:

- Upcoming capex for speciality chemical and HPP to aid value added business revenue mix and thereby group return ratios
- Potential entry into other key segments of fluorine molecules
- Increase in custom synthesis/CRAMS business revenue

Alternate Stock Idea: Apart from Navin Fluorine, in our chemical coverage, we also like Neogen Chemical.


- Trigger for Neogen Chemical's future revenue growth would be increasing **CRAMS** opportunity
- BUY with a target price of ₹ 2160

NAVIN FLUORINE

HOLD

Particulars	
Particular	Amount
Market cap (₹ Crore)	18,424
FY22 Total Debt (₹ Crore)	104
FY22 Cash & Inv (₹ Crore)	200
EV (₹ Crore)	18,328
52 Week H/L	4339/3124
Equity Capital (₹ Crore)	9.9
Face Value (₹)	2





BSE Sensex (LHS) = Navin Flourine (RHS)

Recent event & key risks

- New deal win worth ₹ 600 crore at peak utilisation
- Key Risk: (i) Cancellation of any order or slowdown in order booking, (ii) Sharper than expected improvement in gross margins

Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Dhavan Shah dhavan.shah@icicisecurities.com

(₹ Crore)	FY19	FY20	FY21	FY22	5 year CAGR (FY17-22)	FY23E	FY24E	2 year CAGR (FY22-24E)
Net Revenue	995.9	1,061.6	1,179.4	1,453.4	14.4%	2,003.3	2,673.9	35.6%
EBITDA	218.4	263.5	309.3	354.8	17.4%	500.8	695.2	40.0%
EBITDA Margins (%)	21.9%	24.8%	26.2%	24.4%		25.0%	26.0%	
Adj.PAT	149.1	179.1	222.9	259.0	13.7%	333.9	444.8	31.0%
Adj. EPS (₹)	30.1	36.2	45.0	52.3		67.4	89.8	
EV/EBITDA	83.3x	68.6x	57.5x	51.7x		36.9x	27.0x	
P/E	123.5x	102.9x	82.6x	71.2x		55.2x	41.5x	
ROE (%)	13.9	12.7	13.6	14.0		15.8	18.0	
ROCE (%)	20.9	18.4	21.0	17.8		19.4	20.3	

Source: Company, ICICI Direct Research

Result Update

🜈 Result Update | Navin Fluorine

Key takeaways of recent quarter & conference call highlight

Q4FY22 Results: Decent growth across all segment led performance

- High value business: Revenues were up 19.3% YoY to ₹ 247 crore, led by both speciality chemical and CRAMS segments. The revenue from speciality chemical was up 21% YoY to ₹ 159 crore while the same from CRAMS remained higher by 16% YoY to ₹ 88 crore
- Legacy business: Revenue increased 29.1% YoY to ₹ 151 crore, driven by 20.3% YoY growth in the inorganic fluoride business to ₹ 71 crore while refrigerant business was up 37.9% YoY to ₹ 80 crore

Q4FY22 Earnings Conference Call highlights

1. Specialty Chemicals -

- Achieved record quarterly and annual revenues
- Price hike initiated to offset high input costs
- Strong pipeline of growth opportunities, especially in agrochemicals, driven by principles of 3P: Product, Platform & Partnership

2. CRAMS –

- Achieved record annual sales in FY22
- Focus on expanding project pipeline and further diversifying customer base
- Debottlenecking of CGMP3 approved on the back of robust opportunity pipeline

3. Inorganic Fluorides –

- Achieved record annual sales driven by pricing
- Good traction seen from end user segments especially in India
- Optimised sales mix between domestic & international market for better profitability

4. Refrigerant Business -

- Growth in profitability driven by significant price increase despite higher input costs
- Exports sales impacted due to higher logistics cost
- Sales into non-emissive applications continues to look robust

New capex –New fluoro speciality molecule

- Investment ~₹ 540 crore, peak revenue visibility of ₹ 600 crore
- Funded by Mix of Internal Accruals & Debt
- Project Location Dahej
- Total 50% of total volume will be sold to technological partner. The contract is entered on a <u>cost + basis</u>. Will have no effect in case of escalation price in inputs
- Rest 50% will either be sold in market at market price or will be used internally. The management believes demand for new molecules will remain extremely robust as they are only manufacture of molecule using the technology
- Technology adapted by management is environment friendly process
- Planning to take debt of ₹ 200 crore for new project

Impact on volatility in input cost on various project

- All four projects except MPP are primarily on cost through mechanism
- The company holds heavy inventory for key materials

•

EBITDA margins affected by following reasons:

- Energy cost is high in Q4
 - Employee cost is high in Q4 due to retention of fresh talent
 - Further employee cost as a percentage of sales will have same impact in FY23

Qualitative change due to Russia & Ukraine War – No impact on demand side. Supply side will be affected by escalation in energy cost


Working Capital - Receivables - 90 days (constantly maintained)

-Inventory - 60 days (constantly maintained)


🔗 Result Update | Navin Fluorine

Financial story in charts....


Exhibit 1: Better growth visibility from ongoing capex to aid topline (₹ crore)



Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research

Financial summary

Exhibit 4: Profit and lo	oss stateme	nt			₹ crore
Year end March	FY20	FY21	FY22	FY23E	FY24E
Total Operating Income	1,061.6	1,179.4	1,453.4	2,003.3	2,673.9
Growth (%)	6.6	11.1	23.2	37.8	33.5
Raw Material Expenses	483.8	537.4	665.6	921.5	1,216.6
Employee Cost	130.8	141.7	181.5	240.4	320.9
Other Expenses	183.5	191.0	251.4	340.6	441.2
Total Operating Expenditure	798.1	870.1	1,098.6	1,502.5	1,978.7
EBITDA	263.5	309.3	354.8	500.8	695.2
Growth (%)	20.7	17.4	14.7	41.2	38.8
Other Income	33.3	79.0	39.2	29.2	37.8
Depreciation	37.0	44.2	47.9	80.2	129.3
Net Interest Exp.	2.0	1.8	1.9	4.6	10.6
Other exceptional items	0.0	15.5	0.0	0.0	0.0
PBT	257.8	357.8	344.2	445.2	593.1
Total Tax	-143.6	110.8	81.2	111.3	148.3
PAT	401.4	247.1	263.1	333.9	444.8
Adjusted PAT	179.1	222.9	259.0	333.9	444.8
Growth (%)	20.1	24.5	16.2	28.9	33.2
Adjusted EPS (₹)	36.2	45.0	52.3	67.4	89.8

Source: Company, ICICI Direct Research

Exhibit 6: Balance sheet					₹ crore
Year end March	FY20	FY21	FY22	FY23E	FY24E
Liabilities					
Equity Capital	9.9	9.9	9.9	9.9	9.9
Reserves & Surplus	1,402.3	1,624.0	1,834.3	2,101.4	2,457.2
Total Shareholders Funds	1,412.2	1,633.9	1,844.2	2,111.3	2,467.2
Minority Interest	0.0	0.0	0.0	0.0	0.0
Long Term Borrowings	0.0	0.0	100.0	200.0	400.0
Net Deferred Tax liability	0.0	20.7	20.1	20.1	20.1
Other long term liabilities	28.9	29.1	23.5	32.4	43.3
Long term provisions	10.3	11.8	13.7	18.9	25.2
Current Liabilities and Provisions					
Short term borrowings	1.4	2.5	4.5	4.5	104.5
Trade Payables	98.1	107.4	146.5	208.6	293.0
Other Current Liabilities	74.9	89.0	227.5	313.6	418.6
Short Term Provisions	2.8	3.1	5.4	7.4	9.9
Total Current Liabilities	177.2	202.0	383.9	534.1	826.0
Total Liabilities	1,628.5	1,897.5	2,385.5	2,916.8	3,781.8
Assets					
Net Block	386.0	398.5	415.9	1,252.8	1,763.5
Capital Work in Progress	38.9	94.9	742.1	125.0	50.0
Intangible assets under devl.	0.0	0.0	0.0	0.0	0.0
Goodwill on Consolidation	87.8	87.8	87.8	87.8	87.8
Non-current investments	127.9	14.5	13.9	13.9	13.9
Deferred tax assets	15.1	0.0	0.0	0.0	0.0
Long term loans and advances	9.9	4.3	6.0	8.3	11.0
Other Non Current Assets	179.5	102.8	100.5	118.6	140.6
Current Assets, Loans & Advances					
Current Investments	67.5	84.5	104.2	104.2	104.2
Inventories	157.9	180.4	257.5	384.2	527.5
Sundry Debtors	218.5	284.1	357.7	494.0	659.3
Cash and Bank	283.8	543.9	95.8	47.0	49.0
Loans and Advances	4.5	2.7	0.5	0.5	0.5
Other Current assets	51.4	99.2	203.5	280.6	374.5
Current Assets	783.6	1,194.7	1,019.3	1,310.5	1,714.9
Total Assets	1,628.5	1,897.5	2,385.5	2,916.8	3,781.8

Exhibit 5: Cash flow st	atement			;	₹ crore
Year end March	FY20	FY21	FY22	FY23E	FY24E
PBT & Extraordinary	257.8	357.8	344.2	445.2	593.1
Add: Depreciation	37.0	44.2	47.9	80.2	129.3
After other adjustments					
(Inc) / Dec in Working Capital	-70.6	-125.5	-210.4	-196.1	-218.2
Taxes	-46.2	17.3	-78.1	-111.3	-148.3
Others	-21.3	-56.6	-28.9	4.6	10.6
CF from operating activities	156.7	237.3	74.7	222.6	366.5
Purchase of Fixed Assets	-107.7	-98.7	-578.9	-300.0	-565.0
Others	192.9	-138.4	406.5	0.0	0.0
CF from investing activities	85.1	-237.1	-172.4	-300.0	-565.0
Issue/(Buy back) of Equity	1.2	1.4	2.7	0.0	0.0
Inc/(dec) in loan funds	-8.7	1.1	102.0	100.0	300.0
Dividned paid & dividend tax	-71.4	-39.4	-54.2	-66.8	-89.0
Others	-2.0	-8.2	-9.0	-4.6	-10.6
CF from financing activities	-80.9	-45.1	41.5	28.6	200.4
Net cash flow	160.9	-44.9	-56.1	-48.8	1.9
Opening cash	37.0	283.8	543.9	95.8	47.0
Closing cash	283.8	543.9	95.8	47.0	49.0

Source: Company, ICICI Direct Research

Year end March	FY20	FY21	FY22	FY23E	FY24E
Per share data (₹)					
Adj. EPS	36.2	45.0	52.3	67.4	89.8
Adj. Cash EPS	43.7	54.0	61.9	83.6	115.9
BV	285.3	330.1	372.2	426.1	497.9
DPS	7.0	11.0	11.0	13.5	18.0
Operating Ratios (%)					
Gross Margin (%)	54.4	54.4	54.2	54.0	54.5
EBITDA Margin (%)	24.8	26.2	24.4	25.0	26.0
PAT Margin (%)	16.9	18.9	17.8	16.7	16.6
Debtor Days	75	88	90	90	90
Inventory Days	54	56	65	70	72
Creditor Days	34	33	37	38	40
Cash Conversion Cycle	96	110	118	122	122
<u>Return Ratios (%)</u>					
Return on Assets (%)	11.0	11.7	10.9	11.4	11.8
RoCE (%)	18.4	21.0	17.8	19.4	20.3
RoE (%)	12.7	13.6	14.0	15.8	18.0
<u>Solvency</u>					
Total Debt / Equity	0.0	0.0	0.1	0.1	0.2
Interest Coverage	129.9	187.2	182.2	97.1	56.8
Current Ratio	4.4	5.9	2.7	2.5	2.1
Quick Ratio	3.5	5.0	2.0	1.7	1.4
Valuation Ratios (x)					
ev/ebitda	68.6	57.5	51.7	36.9	27.0
P/E	102.9	82.6	71.2	55.2	41.5
P/B	13.0	11.3	10.0	8.7	7.5
EV/Sales	17.0	15.1	12.6	9.2	7.0

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

Exhibit 8: ICICI Direct coverage universe (Chemicals)

Compony	CMP	CMP		M Cap		EPS (₹)		P/E (x)		EV/EBITDA (x)			RoCE (%)			RoE (%)			
Company	(र)	TP(₹)	Rating	(₹ Cr)	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E
SRF	2513	3,065	Buy	81,517	40.4	63.7	73.4	62.2	39.4	34.2	37.2	25.9	22.5	18.7	24.3	24.0	17.5	23.5	22.9
PI Industries	2848	3,375	Buy	44,358	48.6	55.4	70.1	58.6	51.4	40.7	39.3	34.4	27.6	17.2	17.2	18.8	13.8	13.8	15.0
Aarti Industries	888	1,175	Buy	35,154	14.5	37.1	35.1	61.2	23.9	25.3	39.6	19.3	18.8	10.7	17.7	16.0	15.0	22.8	18.0
Tata Chemical	960	1,155	Buy	24,463	10.1	47.5	63.6	95.4	20.2	15.1	18.9	12.5	9.2	1.8	6.6	8.3	4.1	6.6	8.4
Vinati Organics	2099	2,320	Buy	20,493	26.2	31.5	41.8	80.1	66.7	50.2	56.3	49.4	35.2	21.7	23.3	26.0	17.4	18.0	20.0
Sumitomo Chemical	429	520	Buy	21,254	6.9	8.7	10.3	62.0	49.1	41.7	41.8	33.4	28.0	29.8	30.0	28.5	22.4	22.6	21.4
Navin Fluorine	3722	4,040	Hold	18,443	45.0	52.3	67.4	82.6	71.2	55.2	57.5	51.7	36.9	21.0	17.8	19.4	13.6	14.0	15.8
Rallis India	235	235	Reduce	4,937	11.4	8.4	8.9	20.6	27.8	26.5	14.5	17.4	17.3	18.0	12.7	11.6	13.9	9.7	9.5
Sudarshan chemical	523	695	Buy	3,723	20.4	19.7	25.7	25.7	26.6	20.4	15.7	15.9	12.7	19.0	16.1	18.2	15.2	13.6	16.2
Neogen Chemicals	1549	2,160	Buy	4,142	13.4	16.5	33.5	115.4	93.8	46.3	63.3	47.4	30.6	15.1	11.2	16.9	17.1	9.3	16.0
Astec Lifesciences	1875	2,215	Buy	3,675	33.2	45.1	54.8	56.5	41.6	34.2	34.6	25.6	21.6	18.9	19.3	17.7	21.0	22.3	21.3
Source: Pleamborg ICICI D	iroct Pocoarch																		

ICICI Direct Research

Source: Bloomberg, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA, Dhavan Shah, MS (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report may not be suitable for appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be bubject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.